Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. OM
stocks logo

OM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
26.15M
-11.26%
-0.682
-87.7%
29.22M
-1.79%
-0.757
-76.65%
31.31M
-0.34%
-0.780
-7.14%
Estimates Revision
The market is revising Downward the revenue expectations for Outset Medical, Inc. (OM) for FY2025, with the revenue forecasts being adjusted by -5.86% over the past three months. During the same period, the stock price has changed by -66.31%.
Revenue Estimates for FY2025
Revise Downward
down Image
-5.86%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.6%
In Past 3 Month
Stock Price
Go Down
down Image
-66.31%
In Past 3 Month
Wall Street analysts forecast OM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OM is 15.75 USD with a low forecast of 14.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast OM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OM is 15.75 USD with a low forecast of 14.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.720
sliders
Low
14.00
Averages
15.75
High
17.00
Current: 4.720
sliders
Low
14.00
Averages
15.75
High
17.00
BTIG
Marie Thibault
Buy
downgrade
$39 -> $17
2025-11-11
Reason
BTIG
Marie Thibault
Price Target
$39 -> $17
2025-11-11
downgrade
Buy
Reason
BTIG analyst Marie Thibault lowered the firm's price target on Outset Medical to $17 from $39 and keeps a Buy rating on the shares. The company's Q3 revenue of $29.4M fell short of the consensus estimate as Consumables revenue of $12.2M was below consensus of $14.7M, the analyst tells investors in a research note. The firm adds it is surprised by the shortfall as it viewed the guidance as relatively conservative following a strong Q2 print that included an uptick in Console revenue.
Stifel
Buy
downgrade
$17 -> $14
2025-11-11
Reason
Stifel
Price Target
$17 -> $14
2025-11-11
downgrade
Buy
Reason
Stifel lowered the firm's price target on Outset Medical to $14 from $17 and keeps a Buy rating on the shares. Softer-than-anticipated Consumable sales performance pushed total revenues below the firm's and consensus estimate, while the company highlighted their expectation for further delays in enterprise deal timing to continue and therefore lowered full-year guidance by about $7M at the midpoint, or more than the Q3 miss, the analyst tells investors. However, the "strong pipeline argues for better performance ahead," the analyst contends.
TD Cowen
Joshua Jennings
Buy
downgrade
$25 -> $15
2025-11-11
Reason
TD Cowen
Joshua Jennings
Price Target
$25 -> $15
2025-11-11
downgrade
Buy
Reason
TD Cowen analyst Joshua Jennings lowered the firm's price target on Outset Medical to $15 from $25 and keeps a Buy rating on the shares. The firm lower its target to reflect slightly slower-than-expected progress in the ongoing turnaround.
RBC Capital
Shagun Singh
Sector Perform
downgrade
$22 -> $17
2025-11-11
Reason
RBC Capital
Shagun Singh
Price Target
$22 -> $17
2025-11-11
downgrade
Sector Perform
Reason
RBC Capital analyst Shagun Singh lowered the firm's price target on Outset Medical to $17 from $22 and keeps a Sector Perform rating on the shares. The company delivered a 4% revenue miss and lowered 2025 guide by 5% due to delayed closing of several large deals forecasted for the second half of 2025 and potential impact from the Q4 departure of Head of Sales, the analyst tells investors in a research note. Outset Q4 guide implies accelerating sequential declines that may prove conservative however, the firm added.
BTIG
Marie Thibault
Buy
downgrade
$45 -> $37
2025-07-14
Reason
BTIG
Marie Thibault
Price Target
$45 -> $37
2025-07-14
downgrade
Buy
Reason
BTIG analyst Marie Thibault lowered the firm's price target on Outset Medical to $37 from $45 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results in MedTech. Healthcare was a laggard in Q2 relative to the S&P, and early into Q3, MedTech is underperforming as fears of Medicaid cuts and hospital closures weigh on the sector following recent legislation, the analyst tells investors in a research note. The fears are likely overblown, though the earnings season is likely to offer a mixed picture as sentiment is extremely binary right now, with some companies pushing extreme valuations and others "left for dead", BTIG notes. The firm adds however that on one hand, inflation is calm, markets are at highs, and Fx has turned demonstrably favorable.
RBC Capital
Sector Perform
maintain
$14 -> $21
2025-05-20
Reason
RBC Capital
Price Target
$14 -> $21
2025-05-20
maintain
Sector Perform
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Outset Medical Inc (OM.O) is -1.63, compared to its 5-year average forward P/E of -8.58. For a more detailed relative valuation and DCF analysis to assess Outset Medical Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.58
Current PE
-1.63
Overvalued PE
-1.45
Undervalued PE
-15.71

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-7.76
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-1.42
Undervalued EV/EBITDA
-14.10

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
8.26
Current PS
0.00
Overvalued PS
16.29
Undervalued PS
0.22
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

OM News & Events

Events Timeline

(ET)
2025-11-10
16:34:43
Outset Medical revises FY25 revenue forecast down to $115M-$120M from previous estimate of $122M-$126M.
select
2025-11-10
16:33:22
Outset Medical announces Q3 earnings per share of $1.00, surpassing consensus estimate of 65 cents.
select
2025-09-03 (ET)
2025-09-03
09:06:44
Outset Medical Partners with Northwest Kidney Centers
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-03Newsfilter
PinnedOsisko Metals Completes $32.48 Million Private Placement with Strategic Investors
  • Financing Scale: Osisko Metals plans to complete a non-brokered private placement of approximately 67,666,666 common shares at $0.48 each, expecting gross proceeds of about $32.48 million, which will enhance the company's financial strength to advance its projects.
  • Strategic Investor Participation: Hudbay Minerals is set to subscribe for 29,166,666 shares, while Agnico Eagle intends to subscribe for 26,000,000 shares, reflecting strong confidence in the Gaspé Copper project and further solidifying Osisko's shareholder base.
  • Shareholder Rights Agreement: An investor rights agreement between Hudbay and Osisko grants Hudbay future top-up rights and board representation, with Hudbay expected to hold approximately 4.3% of shares post-financing, increasing its influence within the company.
  • Use of Funds: The net proceeds from this financing will be directed towards advancing the Gaspé Copper project, including drilling, permitting, and technical studies, with the closing expected around December 16, 2025, supporting the company's long-term growth in the critical metals sector.
[object Object]
Preview
8.5
12-03Globenewswire
Osisko Metals Completes $32.48 Million Private Placement with Strategic Investors
  • Financing Scale: Osisko Metals plans to issue approximately 67,666,666 common shares at $0.48 each, expecting total gross proceeds of $32.48 million, which demonstrates the company's strong appeal in the capital markets.
  • Strategic Investor Participation: Hudbay Minerals is set to subscribe for 29,166,666 shares, while Agnico Eagle intends to acquire 26,000,000 shares, indicating strong confidence in the Gaspé Copper project and enhancing the company's shareholder base.
  • Shareholder Rights Agreement: Hudbay has entered into an investor rights agreement with Osisko Metals, granting it future top-up rights and board representation, which is expected to strengthen its influence within the company and optimize governance structures.
  • Use of Proceeds: The net proceeds from this financing will be directed towards advancing the Gaspé Copper project through drilling, permitting, and technical studies, which is anticipated to accelerate project development and enhance the company's competitiveness in the critical metals sector.
[object Object]
Preview
7.0
11-29PRnewswire
Outset Medical Faces Investigation After Q3 Earnings Miss, Stock Plummets 48%
  • Earnings Miss: Outset Medical reported a non-GAAP loss of –$0.69 per share for Q3 2025, missing consensus estimates by $0.03, with revenue of $29.43 million falling short by $1.27 million, indicating significant financial challenges for the company.
  • Guidance Downgrade: The company lowered its full-year 2025 revenue guidance to $115–$120 million from a previous range of $122–$126 million, citing delays in several large anticipated opportunities, which could adversely affect future market performance.
  • Stock Plunge: Following the earnings announcement, Outset Medical's stock price plummeted by $5.85, or 48.47%, closing at $6.22 per share on November 11, 2025, reflecting strong investor concerns about the company's outlook.
  • Legal Investigation: Edelson Lechtzin LLP is investigating potential violations of federal securities laws by Outset Medical, which may expose the company to legal risks and further impact its market credibility and shareholder value.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Outset Medical Inc (OM) stock price today?

The current price of OM is 4.72 USD — it has increased 9.51 % in the last trading day.

arrow icon

What is Outset Medical Inc (OM)'s business?

Outset Medical, Inc. is a medical technology company. It offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. It designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. Tablo comprises various components, including Tablo Console, Tablo Cartridge, and Tablo Data Ecosystem. Tablo Console is a proprietary, compact, mobile and versatile machine consisting of an integrated water purification, on-demand dialysate production system and simple-to-use touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.

arrow icon

What is the price predicton of OM Stock?

Wall Street analysts forecast OM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OM is 15.75 USD with a low forecast of 14.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Outset Medical Inc (OM)'s revenue for the last quarter?

Outset Medical Inc revenue for the last quarter amounts to 29.43M USD, increased 2.67 % YoY.

arrow icon

What is Outset Medical Inc (OM)'s earnings per share (EPS) for the last quarter?

Outset Medical Inc. EPS for the last quarter amounts to -1.00 USD, decreased -87.95 % YoY.

arrow icon

What changes have occurred in the market's expectations for Outset Medical Inc (OM)'s fundamentals?

The market is revising Downward the revenue expectations for Outset Medical, Inc. (OM) for FY2025, with the revenue forecasts being adjusted by -5.86% over the past three months. During the same period, the stock price has changed by -66.31%.
arrow icon

How many employees does Outset Medical Inc (OM). have?

Outset Medical Inc (OM) has 354 emplpoyees as of December 05 2025.

arrow icon

What is Outset Medical Inc (OM) market cap?

Today OM has the market capitalization of 85.68M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free